Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia

Inclusion Criteria: * Men and women between the ages 18 to 70 years * Residing within the states of Missouri or Illinois * Complaints of odors of certain things or everything are distorted * Olfactory dysfunction that has persisted for \>2 months after suspected COVID-19 infection * Ability to read, write, and understand English Exclusion Criteria: * History of olfactory dysfunction prior to COVID-19 infection * Any use of concomitant therapies specifically for the treatment of olfactory dysfunction * History of olfactory dysfunction of longer than 12 months * History of bipolar disorder as SSRIs can theoretically destabilize bipolar disorder * Participants with symptoms of depression as evidenced by a score of 10 or greater on the Patient Health Questionnaire-9 (PHQ-9).95 The PHQ-9 is a nine-item questionnaire designed to assess and aid in diagnosing patients with depression in clinical and community settings. * History of neurodegenerative disease (i.e., Alzheimer's dementia, Parkinson's disease, Lewy body dementia, frontotemporal dementia) * History of chronic rhinosinusitis or sinus surgery * Pregnant or breastfeeding mothers. * Already enrolled in another COVID 19 medication trial or receipt of monoclonal antibody infusion. * Taking donepezil or fluoxetine (rationale: these drugs are S1R agonists) or sertraline (a S1R antagonist). * Participants taking theophylline, tizanidine, clozapine, or olanzapine (drugs with a narrow therapeutic index that are primarily metaboli…